SGMO_OUT_1 [2025-04-04 04:05:02 -0400] 3331 Bytes | 886 tokens | Cum: 886 tkns (11.07% of 8k)
==========================================================================

Booyah, my friends! It's already 4:05:02 AM on Fri Apr 04, 2025 -0400, and I've got my eyes locked on Sangamo Therapeutics (SGMO), pushing up to 0.89 from 0.6223. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Sangamo Therapeutics (SGMO)
IPO: 2000-04-06 (25 Years Ago)
Market Cap: $133,477,751
Shares Outstanding: 224,710,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Here’s the first list of news for Sangamo Therapeutics:

C1 - Apr-03-25 04:01PM - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
C2 - Mar-18-25 09:00AM - Q4 2024 Sangamo Therapeutics Inc Earnings Call
C3 - Mar-18-25 09:00AM 03:01AM - Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
C4 - Mar-17-25 05:10PM - Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
C5 - Mar-17-25 05:10PM 04:20PM - Sangamo: Q4 Earnings Snapshot
C6 - Mar-17-25 05:10PM 04:01PM - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
C7 - Mar-06-25 04:05PM - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
C8 - Feb-06-25 08:05AM - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Prior AI Reports for SGMO:
1. 2025-04-03 – Score: 30 – Target: 0.8271 – Highs: 0.6390 / – / –
company-struggles-amid-negative-returns-and-high-debt

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Sangamo Therapeutics (SGMO).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

SGMO_OUT_3 [2025-04-04 04:05:08 -0400] 1098 Bytes | 303 tokens | Cum: 1192 tkns (14.90% of 8k)
==========================================================================

Showing C4 (chunk 1 of 5): C4:
**Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates**
Date: Mar-17-25 05:10PM
Source: (Zacks)
URL: https://finance.yahoo.com/news/sangamo-therapeutics-sgmo-reports-q4-211004745.html

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this drug developer would post a loss of $0.03 per share when it actually produced earnings of $0.04, delivering a surprise of 233.33%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Sangamo , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $7.55 million for the q

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_5 [2025-04-04 04:05:09 -0400] 1012 Bytes | 312 tokens | Cum: 1620 tkns (20.25% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T07:02:29Z - Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday - Guess (NYSE:GES), American Share...
A2 - 2025-04-04T02:26:50Z - RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks Today - Five Below (NASDAQ:FIVE), Bank of America (...
A3 - 2025-04-04T02:27:06Z - RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks Today - Five Below (NASDAQ:FIVE), Bank of America (...
A4 - 2025-04-03T21:05:48Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX)...
A5 - 2025-04-03T20:28:06Z - Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SGMO_OUT_7 [2025-04-04 04:05:15 -0400] 1098 Bytes | 307 tokens | Cum: 1929 tkns (24.11% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday - Guess (NYSE:GES), American Shared Hospital (AMEX:AMS)**Date: 2025-04-04Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-fridayWith U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects American Shared Hospital Services AMS to report quarterly earnings at 1 cent per share on revenue of $7.70 million before the opening bell, according to data from Benzinga Pro. American Shared Hospital Services shares rose 0.3% to $2.97 in after-hours trading. Guess? Inc. GES reported upbeat results for its fourth quarter and named Alberto Toni as CFO. The company said it sees FY26 revenue to increase 3.9% - 6.2% in U

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_9 [2025-04-04 04:05:23 -0400] 1098 Bytes | 287 tokens | Cum: 2378 tkns (29.73% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): S Dollars and adjusted EPS of $1.32 - $1.76. Guess shares fell 2.4% to $9.80 in the after-hours trading session. NeuroOne Medical Technologies Corp. NMTC disclosed a common stock public offering. NeuroOne Medical shares dipped 36.1% to $0.5499 in the after-hours trading session.

Check out our premarket coverage here

Simulations Plus Inc. SLP posted stronger-than-expected results for its second quarter and issued upbeat FY25 earnings forecast. Simulations Plus shares gained 2.5% to $24.41 in the after-hours trading session. Sangamo Therapeutics Inc. SGMO announced a new agreement with pharmaceutical giant Eli Lilly And Co LLY, granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Sangamo Therapeutics shares jumped 47.7% to $0.9193 in after-hours trading.

Check This Out:

Top 3 Risk Off S

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_11 [2025-04-04 04:05:24 -0400] 1194 Bytes | 365 tokens | Cum: 2865 tkns (35.81% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-18T10:16:53Z - US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
B2 - 2025-02-21T18:00:00Z - Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
B3 - 2025-01-02T07:30:00Z - Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
B4 - 2024-12-31T14:14:19Z - Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
B5 - 2024-12-08T13:00:00Z - mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider
B6 - 2024-11-22T07:27:00Z - Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SGMO_OUT_13 [2025-04-04 04:05:26 -0400] 742 Bytes | 207 tokens | Cum: 3074 tkns (38.42% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/25/03/44372544/us-stocks-swing-as-futures-turn-flat-ahead-of-fomc-meeting-analysts-say-only-certainty-is-that-things-will-remainU.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_15 [2025-04-04 04:05:27 -0400] 1058 Bytes | 287 tokens | Cum: 3406 tkns (42.58% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-17 8-K Item 2.02 Results of Oper and Fin Cond.

On March 17, 2025, Sangamo Therapeutics, Inc. (Sangamo) issued a press release announcing its financial results for the year ended December 31, 2024 (the Press Release).

A copy of the Press Release is furnished hereto a...

S2 - 2025-03-17 8-K Item 2.02 Results of Oper and Fin Cond.

On March 17, 2025, Sangamo Therapeutics, Inc. (Sangamo) issued a press release announcing its financial results for the year ended December 31, 2024 (the Press Release).

A copy of the Press Release is furnished hereto a...

S3 - 2025-03-17 10-K ITEM 7 MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The discussion in Mgts Discussion and Analysis of Fin Cond and Results of Oper contains trend analysis, estimates and other forward-looking statements within the...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SGMO_OUT_17 [2025-04-04 04:05:28 -0400] 1098 Bytes | 287 tokens | Cum: 3695 tkns (46.19% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 17, 2025, Sangamo Therapeutics, Inc. (Sangamo) issued a press release announcing its financial results for the year ended December 31, 2024 (the Press Release).

A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Secu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_19 [2025-04-04 04:05:28 -0400] 360 Bytes | 100 tokens | Cum: 3797 tkns (47.46% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): rities and Exchange Commission made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SGMO_OUT_21 [2025-04-04 04:05:40 -0400] 6500 Bytes | 1938 tokens | Cum: 5737 tkns (71.71% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-------------------------+
| Volume: 15,003,650 | Perf Month: -28.87% | Option/Short: Yes / Yes | Sales Y/Y TTM: -67.20% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 5.37M | Perf Quarter: -38.99% | Short Float: 13.47% | ROE: -187.83% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 2.79 | Index: - | Short Ratio: 5.38 | ROI: -202.41% |
+--------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 32.00 | Market Cap: 139.84M | Short Interest: 28.91M | Sales Surprise: -35.46% |
+--------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.10 | Shs Outstand: 224.71M | Beta: 1.50 | EPS Surprise: -20.48% |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -27.16% | Shs Float: 214.59M | Sales Q/Q: 269.78% | P/E: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -37.96% | Inst Own: 27.61% | Sales past 5Y: 0.15% | Earnings: Mar 17 AMC |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -46.60% | Insider Own: 4.50% | Employees: 183 | |
+--------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -27.41% | Insider Trans: 0.00% | Debt/Eq: 1.34 | |
+--------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Macrae Sandy (PRESIDENT, CEO AND DIRECTOR) on 2025-02-24
- Common Stock: 7488 shares at $1 (D)
- Common Stock: 10663 shares at $0.9561 (D)
- Common Stock: 375000 shares at $0 (D)
- Stock Option (Right to Buy): 1750000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Davis Gregory D (Head of Research & Technology) on 2025-02-24
- Common Stock: 705 shares at $1 (D)
- Common Stock: 507 shares at $0.9561 (D)
- Common Stock: 49726 shares at $0 (D)
- Stock Option (Right to Buy): 99454 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Dubois-Stringfellow Nathalie (SVP-CHIEF DEVELOPMENT OFFICER) on 2025-02-24
- Common Stock: 1792 shares at $1 (D)
- Common Stock: 1513 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Duraibabu Prathyusha (SVP, CHIEF FINANCIAL OFFICER) on 2025-02-24
- Common Stock: 1792 shares at $1 (D)
- Common Stock: 1375 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Willoughby Scott B. (SVP, GEN. COUNSEL & SECRETARY) on 2025-02-24
- Common Stock: 1434 shares at $1 (D)
- Common Stock: 1375 shares at $0.9561 (D)
- Common Stock: 120000 shares at $0 (D)
- Stock Option (Right to Buy): 560000 shares at $0 (D)

Inside Trans: SANGAMO THERAPEUTICS, INC (SGMO) by Duraibabu Prathyusha (SVP, CHIEF FINANCIAL OFFICER) on 2025-01-22
- Common Stock: 129242 shares at $1.15 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 57800000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -97941000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.6223
Average Volume: 7341401.77
30-Day High: 1.04
30-Day Low: 0.5701

[Detailed Financials: TTM 2024]
- Total Assets: $101,635,000.0
- Total Liabilities: $78,865,000.0
- Total Equity: $22,770,000.0
- Current Assets: $51,691,000.0
- Current Liabilities: $45,805,000.0

[Income Statement: TTM 2024]
- Revenue: $57,800,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.49

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-3,286,000.0

[Detailed Financials: FY 2024]
- Total Assets: $101,635,000.0
- Total Liabilities: $78,865,000.0
- Total Equity: $22,770,000.0
- Current Assets: $51,691,000.0
- Current Liabilities: $45,805,000.0

[Income Statement: FY 2024]
- Revenue: $57,800,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.49

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-3,286,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

SGMO_OUT_23 [2025-04-04 04:05:42 -0400] 687 Bytes | 169 tokens | Cum: 6220 tkns (77.75% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

SGMO_IN_25 [2025-04-04 04:05:43 -0400] 126 Bytes | 29 tokens | Cum: 6278 tkns (78.47% of 8k)
==========================================================================

====================================
[2025-04-04 04:05:43] # Analysis Completed
Elapsed Time: 40.84 seconds